CREPT-618 / He Ya (Beijing) Pharmaceutical Technology - LARVOL DELTA

Crept-618: First GalNAc-siRNA targeting CREPT reverses HCC immune evasion and synergizes with anti-PD-1 (AACR 2026) - "CREPT drives HCC growth and immune evasion by repressing CCL5, blocking T-cell recruitment via the CCL5-CCR5 axis. CREPT-618—the first siRNA targeting CREPT—silences this oncogenic hub, restores CCL5 signaling, converts "cold" tumors to "hot", and synergizes with anti-PD-1. These preclinical data will enable a first-in-human trial; preliminary human safety and CREPT knockdown data will be presented at AACR."

First-in-human • IO biomarker • Hepatocellular Cancer • Oncology • Solid Tumor • CD8 • HDAC1 • IFNG • IRF1

Clinical trial of safety, tolerability and preliminary efficacy of crept-618 combined with tirelizumab injection in the treatment of unresectable hepatocellular carcinoma (ChiCTR) - P=N/A | N=10 | Not yet recruiting | Sponsor: People's Hospital of Deyang City; People's Hospital of Deyang City

New trial • Hepatocellular Cancer • Oncology • Solid Tumor • MUC4